Rob Dillard

DocwireNews

Last week, the U.S. Food and Drug Administration (FDA) <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treatment-peanut-allergy-children">approved</a> Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], a powder that reduces allergic reactions, including <a href="https://www.docwirenews.com/conference-coverage/helping-families-and-schools-manage-anaphylaxis/">anaphylaxis</a>, that may occur following accidental exposure to peanuts. Palforzia can be administered to children ages 4 through 17 with a confirmed diagnosis of peanut allergy. However, children taking Palforzia must continue to avoid consuming peanuts.The efficacy of Palforzia was assessed in a randomized, double-blind, placebo-controlled study conducted in the U.S., Canada and Europe comprised of approximately 500 peanut-allergic individuals. Researchers evaluated the percentage of study participants tolerating an oral dose of 600 mg of peanut protein (twice the daily maintenance dose of Palforzia) with no more than mild allergic symptoms after 6 months of maintenance treatment. According to the study results, 67.2% of Palforzia recipients tolerated a 600 mg dose of peanut protein, juxtaposed to 4% of recipients in the placebo arm.Palforzia&rsquo;s safety was tested in two double-blind, placebo-controlled studies comprised of approximately 700 peanut-allergic individuals. The results showed that the most common side effects of Palforzia were:<ul>
<li>Abdominal pain</li>
<li>Vomiting</li>
<li>Nausea</li>
<li>Tingling in the mouth</li>
<li>Itching</li>
<li>Cough</li>
<li>Runny nose</li>
<li>Throat irritation and tightness</li>
<li>Hives</li>
<li>Wheezing and shortness of breath</li>
<li>Anaphylaxis</li>
</ul>The FDA noted that Palforzia should not be administered to patients with uncontrolled asthma.<img loading="lazy" decoding="async" class="alignnone size-medium wp-image-4823867" src="https://mumcdnstorage.blob.core.windows.net/dwnews/2020/02/Homepage_2.3.20_AddtoArticle-300x202.jpg" alt="" width="300" height="202"><h2>Three Phase Treatment</h2>Treatment with Palforzia, which is manufactured from peanuts and packaged in pull-apart color-coded capsules, consists of three phases: Initial Dose Escalation, Up-Dosing, and Maintenance. The Initial Dose Escalation phase is administered on a single day. The Up-Dosing phase includes 11 increasing dose levels and occurs over several months. The FDA noted that both the initial Dose Escalation, and the first dose of each Up-Dosing level, are administered under supervision of a healthcare professional in a healthcare setting with the ability to manage potentially severe allergic reactions, including anaphylaxis. Also, while anaphylaxis may occur at any time during Palforzia therapy, patients are at the highest risk during and after the Initial Dose Escalation and the first dose of each Up-Dosing level.During the Up-Dosing phase, if a patient tolerates the first dose of an increased dose level, the patient may continue that dose level daily at home. Subsequent to the completion of all Up-Dosing levels, the patient may begin the daily maintenance dose. Any patient who experiences certain allergic reactions due to Palforzia may need to either discontinue treatment or have their dosing schedule modified.To allay the risk of anaphylaxis associated with Palforzia, the FDA is requiring a Risk Evaluation and Mitigation Strategy (REMS) with this approval, which includes elements to assure safe use. Palforzia will only be available through specially certified healthcare providers, health care settings, and pharmacies to patients who are enrolled in the REMS program.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
FDA Approves First Drug For Treatment Of Peanut Allergy For Children<a href="https://t.co/xtoRosArhT">https://t.co/xtoRosArhT</a><a href="https://twitter.com/hashtag/news?src=hash&amp;ref_src=twsrc%5Etfw">#news</a> <a href="https://twitter.com/hashtag/pharma?src=hash&amp;ref_src=twsrc%5Etfw">#pharma</a> <a href="https://twitter.com/hashtag/pharmiweb?src=hash&amp;ref_src=twsrc%5Etfw">#pharmiweb</a>
&mdash; Pharma &amp; Life Science News (@pharminews) <a href="https://twitter.com/pharminews/status/1223378159644696578?ref_src=twsrc%5Etfw">January 31, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&ldquo;Peanut allergy affects approximately 1 million children in the U.S. and only 1 out of 5 of these children will outgrow their allergy. Because there is no cure, allergic individuals must strictly avoid exposure to prevent severe and potentially life-threatening reactions,&rdquo; said Peter Marks, M.D., Ph.D., director of the FDA&rsquo;s Center for Biologics Evaluation and Research in an FDA <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treatment-peanut-allergy-children">press release</a>.&ldquo;Even with strict avoidance, inadvertent exposures can and do occur. When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
FDA approves first drug for treatment of peanut allergy for children <a href="https://t.co/sH2d6273ho">https://t.co/sH2d6273ho</a> <a href="https://t.co/nKSsTYtxoV">pic.twitter.com/nKSsTYtxoV</a>
&mdash; World Pharma News (@WorldPharmaNews) <a href="https://twitter.com/WorldPharmaNews/status/1223421342776623105?ref_src=twsrc%5Etfw">February 1, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
FDA approves first drug for treatment of peanut allergy for children <a href="https://t.co/ZuGAgwWEUh">https://t.co/ZuGAgwWEUh</a>
&mdash; Matthew Bowdish MD (@MatthewBowdish) <a href="https://twitter.com/MatthewBowdish/status/1223438604921274368?ref_src=twsrc%5Etfw">February 1, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

FDA Approves Palforzia: The First Drug Developed for the Treatment of Peanut Allergy in Children

Future of Medicine

Last week, the U.S. Food and Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], a powder that reduces allergic reactions, including ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe